Back to results
US 12,758,628 B2Granted
Recombinant MVA viruses for intratumoral and/or intravenous administration for treating cancer
AssigneeBavarian Nordic A/S
InventorsHenning Lauterbach, Maria Hinterberger, José Medina Echeverz, Matthias Habjan, Jürgen Hausmann, Markus Kalla
Life of this patent
Estimating the term…
Abstract
The invention relates to a composition and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The composition comprises a recombinant MVA encoding a Tumor Associated Antigen (“TAA”) as well as 4-1BBL and/or CD40L and can be administered to a subject in any suitable manner, including by intravenous and/or intratumoral administration.
Claims8
A recombinant modified Vaccinia virus Ankara (MVA) comprising:
- (i) a nucleic acid encoding HERV-K-env/MEL and having the nucleotide sequence set forth in SEQ ID NO:12 or encoding the amino acid sequence set forth in SEQ ID NO:11;
- (ii) a nucleic acid encoding HERV-K gag;
- (iii) a nucleic acid encoding FOLR1 and PRAME;
- and
- (iv) a nucleic acid encoding 4-1BBL.
2 more elements
Dependencies are inferred from the claim text.